Your session is about to expire
← Back to Search
Pembrolizumab for Breast Cancer (TN-IBC Trial)
TN-IBC Trial Summary
This trial is testing whether a combination of immunotherapy and chemotherapy drugs can shrink tumors in patients with stage III-IV triple negative breast cancer.
- Breast Cancer
TN-IBC Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183TN-IBC Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
How many people are being allowed to participate in this experiment?
"The listing for this trial on clinicaltrials.gov confirms that it is currently open to new enrolments. This experiment was first advertised on March 11th, 2022 and was last updated October 11th of the same year. So far, 30 individuals are needed from 2 separate locations."
Are people still enrolling in this experiment?
"From what is published on clinicaltrials.gov, this study requires more participants and is currently recruiting them. The trial was first posted on March 11th, 2022 and was updated as recently as October 11th, 2022."
Has the Federal Drug Administration given their blessing to Pembrolizumab?
"Pembrolizumab's safety is only partially supported by clinical data, meaning it received a score of 2."
What is Pembrolizumab used to treat?
"Pembrolizumab is a medication that oncologists often prescribe to treat melanoma. It can also help patients who are dealing with neoplasm metastasis, malignant melanoma of skin, and kaposi's sarcoma aids related."
What other types of trials compare to this one?
"Pembrolizumab has completed 2916 Phase 3 trials in 4489 cities and 87 countries since 1997. The first study, sponsored by Alfacell, involved 300 patients."
Share this study with friends
Copy Link
Messenger